News and Updates

nPhase has launched a new AI-powered platform designed to streamline clinical trial design, enhance data management, and accelerate drug development timelines.

Novartis’s Phase 3 trial for del-desiran fails to meet primary endpoints in patients with Myotonic Dystrophy Type 1, halting progress on the ASO therapy.

New clinical trial data reveals how AI-powered imaging is transforming Idiopathic Pulmonary Fibrosis research and the development of the drug ENV101.

SOTIO has dosed the first patient in the CADENCIA-01 trial for SOT109, a CDH17-targeting ADC aimed at treating advanced colorectal cancer.

PhenoNet concludes patient enrollment for its Phase IIb trial of PHENOGENE-1A, a promising investigative therapy for Amyotrophic Lateral Sclerosis (ALS).

Guggenheim identifies a top biotech stock to watch following successful clinical trial results. Explore the impact on growth and market potential here.

Ocugen has initiated a Phase 3 trial for its GA gene therapy. Learn how this breakthrough approach aims to treat advanced macular degeneration.

The FDA has finalized key leadership roles at CDER and CBER, ensuring regulatory stability and scientific continuity while awaiting a new commissioner.

Kazia Therapeutics begins dosing in the PNOC035 study, testing paxalisib as a targeted therapy for aggressive, recurrent pediatric AT/RT brain tumors.

A new AI-driven screening tool is accelerating Alzheimer's clinical trial recruitment by accurately identifying eligible patients through EHR analysis.